CorMedix, Inc. (CRMD) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1152748,
    "name": "CorMedix, Inc.",
    "stock_name": "CorMedix, Inc.",
    "full_name": "CorMedix, Inc.",
    "name_url": "stocks-analysis/cormedix-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "10.64",
    "chg": 0.86,
    "chgp": "8.79%",
    "dir": 1,
    "prev_price": "9.78",
    "mcapval": "951.77",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US21900C3088",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "4.93 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/cormedix-inc-1152748-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "CorMedix Stock Hits Day Low of $9.82 Amid Price Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cormedix-stock-hits-day-low-of-982-amid-price-pressure-3712569",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/CorMedixInc_priceRelatedfactors_3712569.png",
        "date": "2025-11-18 17:25:02",
        "description": "CorMedix, Inc. faced a notable stock decline today, reaching an intraday low. Over the past week and month, the stock has shown decreases, contrasting with the stable performance of the S&P 500. Despite this, CorMedix reported impressive financial growth metrics and maintains a strong market presence."
      },
      {
        "title": "Is CorMedix, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-cormedix-inc-overvalued-or-undervalued-3637682",
        "imagepath": "",
        "date": "2025-10-21 12:07:02",
        "description": "As of 17 October 2025, the valuation grade for CorMedix, Inc. has moved from attractive to very attractive, indicating a strong positive shift in its valuation outlook. The company appears to be undervalued, particularly when considering its PEG ratio of 0.42, which suggests that the stock is trading at a lower price relative to its growth potential. Additionally, the P/E ratio stands at 55, which, while high, is offset by a robust ROCE of 38.54%, indicating efficient capital use.\n\nIn comparison to peers, CorMedix's valuation metrics are compelling; for instance, Xeris Biopharma Holdings, Inc. has a significantly negative P/E of -38.70, highlighting the relative strength of CorMedix. Furthermore, the EV to EBITDA ratio of 57.92 also contrasts sharply with the peer average, reinforcing the attractiveness of CorMedix's valuation. Despite recent underperformance in the short term, with a 1-week return of -5.13..."
      },
      {
        "title": "CorMedix, Inc. Experiences Valuation Adjustment Reflecting Shift in Financial Standing",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cormedix-inc-sees-valuation-grade-upgrade-from-attractive-to-very-attractive-3640605",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/CorMedixInc_valuationdot_3640605.png",
        "date": "2025-10-20 15:51:17",
        "description": "CorMedix, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 55 and a price-to-book value of 8.25. The company demonstrates strong operational efficiency with a PEG ratio of 0.42 and a ROCE of 38.54%, positioning it favorably against peers like Xeris Biopharma Holdings."
      },
      {
        "title": "Is CorMedix, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-cormedix-inc-overvalued-or-undervalued-3634550",
        "imagepath": "",
        "date": "2025-10-20 12:24:22",
        "description": "As of 17 October 2025, the valuation grade for CorMedix, Inc. moved from attractive to very attractive. The company appears to be undervalued, as indicated by its PEG ratio of 0.42, which suggests strong growth potential relative to its price, and a P/E ratio of 55, which, while high, is offset by the company's robust ROCE of 38.54%. In comparison, Xeris Biopharma Holdings, Inc. has a P/E ratio of -38.70, highlighting CorMedix's relative strength in the sector.\n\nDespite recent stock performance showing a decline of 5.13% over the past week and 8.45% over the past month, CorMedix has outperformed the S&P 500 year-to-date with a return of 25.68% compared to the index's 13.30%. This performance, combined with its strong valuation metrics, supports the conclusion that CorMedix, Inc. is undervalued in the current market...."
      },
      {
        "title": "Is CorMedix, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-cormedix-inc-overvalued-or-undervalued-3632087",
        "imagepath": "",
        "date": "2025-10-19 12:02:00",
        "description": "As of 17 October 2025, the valuation grade for CorMedix, Inc. has moved from attractive to very attractive. The company appears to be undervalued, particularly when considering its PEG ratio of 0.42, which suggests strong growth potential relative to its price, alongside a P/E ratio of 55 and an EV to EBITDA of 57.92. In comparison, Xeris Biopharma Holdings, Inc. has a P/E of -38.70, indicating significant challenges, while CorMedix's metrics reflect a more favorable valuation profile.\n\nDespite recent underperformance with a 1-week return of -5.13% compared to the S&P 500's 1.70%, CorMedix has shown resilience with a year-to-date return of 25.68%, outpacing the S&P 500's 13.30%. This performance, combined with its strong return on capital employed (ROCE) of 38.54% and return on equity (ROE) of 14.95%, reinforces the attractiveness of the stock as a long-term investment opportunity...."
      },
      {
        "title": "Is CorMedix, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-cormedix-inc-technically-bullish-or-bearish-3546516",
        "imagepath": "",
        "date": "2025-09-20 19:34:44",
        "description": "As of 10 September 2025, the technical trend for CorMedix, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by daily moving averages indicating mild bullishness, while the weekly MACD and KST are mildly bearish. The Bollinger Bands show a bearish signal on the weekly but mildly bullish on the monthly. The company has outperformed the S&P 500 significantly over the 1Y (61.35% vs. 17.14%) and 3Y (245.86% vs. 70.41%) periods, indicating strong long-term performance despite recent short-term weakness...."
      },
      {
        "title": "Is CorMedix, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-cormedix-inc-overvalued-or-undervalued-3543079",
        "imagepath": "",
        "date": "2025-09-20 18:10:02",
        "description": "As of 7 August 2025, the valuation grade for CorMedix, Inc. has moved from expensive to very attractive, indicating a significant improvement in its perceived value. The company appears to be undervalued, especially given its PEG ratio of 0.42, which suggests strong growth potential relative to its price. Additionally, the P/E ratio stands at 55, while the EV to EBITDA ratio is 57.92, both of which are high but may reflect the company's growth prospects in the pharmaceuticals and biotechnology sector.\n\nIn comparison to its peer, Xeris Biopharma Holdings, Inc., which has a P/E ratio of -38.70 and an EV to EBITDA of 517.94, CorMedix shows a more favorable valuation profile. The company's ROCE of 38.54% and ROE of 14.95% further support the notion of its strong operational efficiency. While CorMedix has faced recent stock declines, with a 1-week return of -10.70% compared to a 1.05% gain in the S&P 500, its ye..."
      },
      {
        "title": "CorMedix Stock Hits Day Low of $11.50 Amid Price Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cormedix-stock-hits-day-low-of-1150-amid-price-pressure-3525997",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/CorMedixInc_priceRelatedfactors_3525997.png",
        "date": "2025-09-17 15:50:43",
        "description": "CorMedix, Inc. faced a significant stock price decline today, reaching an intraday low. However, the company has demonstrated strong financial performance over the past year, with substantial growth in net profit and pre-tax profit, alongside solid operating cash flow and a favorable return on equity."
      }
    ],
    "total": 13,
    "sid": "1152748",
    "stock_news_url": "https://www.marketsmojo.com/news/cormedix-inc-1152748"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

CorMedix Stock Hits Day Low of $9.82 Amid Price Pressure

2025-11-18 17:25:02

CorMedix, Inc. faced a notable stock decline today, reaching an intraday low. Over the past week and month, the stock has shown decreases, contrasting with the stable performance of the S&P 500. Despite this, CorMedix reported impressive financial growth metrics and maintains a strong market presence.

Is CorMedix, Inc. overvalued or undervalued?

2025-10-21 12:07:02

As of 17 October 2025, the valuation grade for CorMedix, Inc. has moved from attractive to very attractive, indicating a strong positive shift in its valuation outlook. The company appears to be undervalued, particularly when considering its PEG ratio of 0.42, which suggests that the stock is trading at a lower price relative to its growth potential. Additionally, the P/E ratio stands at 55, which, while high, is offset by a robust ROCE of 38.54%, indicating efficient capital use. In comparison to peers, CorMedix's valuation metrics are compelling; for instance, Xeris Biopharma Holdings, Inc. has a significantly negative P/E of -38.70, highlighting the relative strength of CorMedix. Furthermore, the EV to EBITDA ratio of 57.92 also contrasts sharply with the peer average, reinforcing the attractiveness of CorMedix's valuation. Despite recent underperformance in the short term, with a 1-week return of -5.13...

CorMedix, Inc. Experiences Valuation Adjustment Reflecting Shift in Financial Standing

2025-10-20 15:51:17

CorMedix, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 55 and a price-to-book value of 8.25. The company demonstrates strong operational efficiency with a PEG ratio of 0.42 and a ROCE of 38.54%, positioning it favorably against peers like Xeris Biopharma Holdings.

Is CorMedix, Inc. overvalued or undervalued?

2025-10-20 12:24:22

As of 17 October 2025, the valuation grade for CorMedix, Inc. moved from attractive to very attractive. The company appears to be undervalued, as indicated by its PEG ratio of 0.42, which suggests strong growth potential relative to its price, and a P/E ratio of 55, which, while high, is offset by the company's robust ROCE of 38.54%. In comparison, Xeris Biopharma Holdings, Inc. has a P/E ratio of -38.70, highlighting CorMedix's relative strength in the sector. Despite recent stock performance showing a decline of 5.13% over the past week and 8.45% over the past month, CorMedix has outperformed the S&P 500 year-to-date with a return of 25.68% compared to the index's 13.30%. This performance, combined with its strong valuation metrics, supports the conclusion that CorMedix, Inc. is undervalued in the current market....

Is CorMedix, Inc. overvalued or undervalued?

2025-10-19 12:02:00

As of 17 October 2025, the valuation grade for CorMedix, Inc. has moved from attractive to very attractive. The company appears to be undervalued, particularly when considering its PEG ratio of 0.42, which suggests strong growth potential relative to its price, alongside a P/E ratio of 55 and an EV to EBITDA of 57.92. In comparison, Xeris Biopharma Holdings, Inc. has a P/E of -38.70, indicating significant challenges, while CorMedix's metrics reflect a more favorable valuation profile. Despite recent underperformance with a 1-week return of -5.13% compared to the S&P 500's 1.70%, CorMedix has shown resilience with a year-to-date return of 25.68%, outpacing the S&P 500's 13.30%. This performance, combined with its strong return on capital employed (ROCE) of 38.54% and return on equity (ROE) of 14.95%, reinforces the attractiveness of the stock as a long-term investment opportunity....

Is CorMedix, Inc. technically bullish or bearish?

2025-09-20 19:34:44

As of 10 September 2025, the technical trend for CorMedix, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by daily moving averages indicating mild bullishness, while the weekly MACD and KST are mildly bearish. The Bollinger Bands show a bearish signal on the weekly but mildly bullish on the monthly. The company has outperformed the S&P 500 significantly over the 1Y (61.35% vs. 17.14%) and 3Y (245.86% vs. 70.41%) periods, indicating strong long-term performance despite recent short-term weakness....

Is CorMedix, Inc. overvalued or undervalued?

2025-09-20 18:10:02

As of 7 August 2025, the valuation grade for CorMedix, Inc. has moved from expensive to very attractive, indicating a significant improvement in its perceived value. The company appears to be undervalued, especially given its PEG ratio of 0.42, which suggests strong growth potential relative to its price. Additionally, the P/E ratio stands at 55, while the EV to EBITDA ratio is 57.92, both of which are high but may reflect the company's growth prospects in the pharmaceuticals and biotechnology sector. In comparison to its peer, Xeris Biopharma Holdings, Inc., which has a P/E ratio of -38.70 and an EV to EBITDA of 517.94, CorMedix shows a more favorable valuation profile. The company's ROCE of 38.54% and ROE of 14.95% further support the notion of its strong operational efficiency. While CorMedix has faced recent stock declines, with a 1-week return of -10.70% compared to a 1.05% gain in the S&P 500, its ye...

CorMedix Stock Hits Day Low of $11.50 Amid Price Pressure

2025-09-17 15:50:43

CorMedix, Inc. faced a significant stock price decline today, reaching an intraday low. However, the company has demonstrated strong financial performance over the past year, with substantial growth in net profit and pre-tax profit, alongside solid operating cash flow and a favorable return on equity.

View All News